[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654706":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":11,"studyPopulation":11,"armGroups":47,"interventions":58,"overallOfficials":11,"centralContacts":68,"locations":74,"responsibleParty":96,"collaborators":11,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":11,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":11,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":11,"overallStatus":77,"whyStopped":11,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Adverse events (AEs)",null,"Evaluation was performed up to Day 36 or Day 72.",{"measure":14,"description":11,"timeFrame":12},"Serious Adverse events (SAEs)",[16,18,21,23,25,27,29,31,33],{"measure":17,"description":11,"timeFrame":12},"Plasma concentration of HRS-4139 in healthy participants",{"measure":19,"description":20,"timeFrame":12},"Peak concentration (Cmax)","PK parameter.",{"measure":22,"description":20,"timeFrame":12},"Time to peak concentration (Tmax)",{"measure":24,"description":20,"timeFrame":12},"Area under the concentration-time curve from time 0 to the last quantifiable time point (AUC0-last)",{"measure":26,"description":20,"timeFrame":12},"Area under the concentration-time curve from time 0 to infinity (AUC0-inf)",{"measure":28,"description":20,"timeFrame":12},"Elimination half-life (t1\u002F2)",{"measure":30,"description":20,"timeFrame":12},"Apparent clearance (CL\u002FF)",{"measure":32,"description":20,"timeFrame":12},"Apparent volume of distribution (Vd\u002FF)",{"measure":34,"description":11,"timeFrame":12},"Incidence and time of onset of Anti drug antibody (ADA) positivity in healthy participants receiving HRS-4139",{"allocation":36,"interventionModel":37,"interventionModelDescription":38,"primaryPurpose":39,"observationalModel":11,"timePerspective":11,"maskingInfo":40},"RANDOMIZED","PARALLEL","Randomized, Double-blind, Placebo-controlled.","TREATMENT",{"masking":41,"maskingDescription":11,"whoMasked":42},"QUADRUPLE",[43,44,45,46],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[48,53],{"label":49,"type":50,"description":11,"interventionNames":51},"HRS-4139 tablet group","EXPERIMENTAL",[52],"Drug: HRS-4139 Tablet",{"label":54,"type":55,"description":11,"interventionNames":56},"HRS-4139 placebo group","PLACEBO_COMPARATOR",[57],"Drug: HRS-4139 Placebo",[59,64],{"type":60,"name":61,"description":62,"armGroupLabels":63,"otherNames":11},"DRUG","HRS-4139 Tablet","HRS-4139 tablet.",[49],{"type":60,"name":65,"description":66,"armGroupLabels":67,"otherNames":11},"HRS-4139 Placebo","HRS-4139 placebo.",[54],[69],{"name":70,"role":71,"phone":72,"phoneExt":11,"email":73},"Meng Fu","CONTACT","+86-0518-82342973","meng.fu@hengrui.com",[75],{"facility":76,"status":77,"city":78,"state":79,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":89},"Xiangya Hospital of Central South University","RECRUITING","Changsha","Hunan","410008","China","CN",{"type":84,"coordinates":85},"Point",[86,87],112.97087,28.19874,{"lat":87,"lon":86},[90,94],{"name":91,"role":71,"phone":92,"phoneExt":11,"email":93},"Gan Zhou","+86-0731-89753401","Zhougan77@163.com",{"name":91,"role":95,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":97,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100654706","phase-1-a-clinical-trial-to-evaluate-the-safety-tolerability-pharmacokinetics-immunogenicity-and-pharmacodynamics-of-hrs-4139-in-healthy-participants-100654706",false,"NCT07802964","A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants","A Randomized, Double-blind, Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a Single Oral Dose of HRS-4139 in Healthy Participants","Inclusion Criteria:\n\n1. Participants who understand the specific procedures of the trial, voluntarily agree to participate in this trial, and provide written informed consent.\n2. Participants aged 18 to 55 years (inclusive) at screening.\n3. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) between 18.0 and 26.0 kg\u002Fm² (inclusive).\n4. Participants who are able to communicate effectively with the investigator, fully understand and comply with all requirements of the trial protocol.\n\nExclusion Criteria:\n\n1. Participants with any disease of the circulatory, endocrine, neurological, digestive, respiratory, hematologic, immunologic, psychiatric, or metabolic systems, or any other condition that may interfere with the trial results.\n2. Participants with a history of malignancy.\n3. Participants with a history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia), or with short QT syndrome or long QT syndrome, or with a family history in first-degree relatives of unexplained sudden death, drowning, or sudden infant death syndrome (SIDS) occurring at ≤ 40 years of age.\n4. Participants who have had an opportunistic infection within 6 months prior to screening; or who have a known history of recurrent or chronic infections, or who have had chronic or recurrent sinusitis, tonsillitis, urinary tract infections, prostatitis, enteritis, etc.\n5. Participants who have had an acute infection with systemic symptoms requiring systemic anti-infective therapy (intravenous or oral) within 4 weeks prior to screening.\n6. Participants who have participated in any clinical trial of a drug or medical device within 3 months prior to screening, where participation is defined as having signed the informed consent and having received the investigational drug or medical device; or Participants who are still within the follow-up period of any clinical study or within 5 elimination half-lives of the study drug at the time of screening, whichever is longer.\n7. Participants who have used any medication (including prescription drugs, over-the-counter medications, Chinese herbal medicines, dietary supplements, etc.) within 2 weeks or within 5 elimination half-lives (whichever is longer) prior to the administration of the study drug; or Participants who plan to use any other medication during the study period.\n8. Participants who have received a live (attenuated) vaccine within 1 month prior to screening or plan to receive such a vaccine during the trial period, with the exception of influenza vaccination.\n9. Participants who have experienced severe trauma or undergone major surgery within 6 months prior to screening, or who plan to undergo surgery during the trial period.\n10. Participants who have donated blood or experienced significant blood loss (≥ 400 mL) within 1 month prior to screening, or who have received a blood transfusion within 2 months prior to screening.",true,"ALL","18 Years","55 Years",{"count":110,"type":111},40,"ESTIMATED","INTERVENTIONAL",[114],"PHASE1","This Phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral dose of HRS-4139 in healthy participants.",[117],"Psoriasis Vulgaris","2026-09-23",{"date":120,"type":121},"2026-09-25","ACTUAL",{"date":123,"type":121},"2026-09-21",{"date":125,"type":111},"2027-04",{"name":5,"class":6},1]